-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 9, BioNTech announced that it has expanded its strategic R&D cooperation with Regeneron, and will jointly promote the clinical trial of BioNTech's candidate cancer vaccine BNT116 in combination with the PD-1 inhibitor Libtayo (cemiplimab) for the treatment of advanced stage Non-small cell lung cancer (NSCLC) patients
BNT116 is a cancer vaccine developed based on BioNTech's FixVac technology platform
▲Introduction to FixVac technology platform (Image source: BioNTech official website)
Previously, the two companies have collaborated to evaluate the cancer vaccine BNT111 in combination with Libtayo in the treatment of advanced melanoma
References:
[1] BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC.
(Original abridged)